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OBJECTIVES We aimed to determine whether growth hormone (GH) resistance is present in patients with
chronic heart failure (CHF) and whether it may be linked to the biochemical response to GH
treatment.
BACKGROUND Acquired GH resistance is a feature of severe illness, in particular, cachexia. In patients with
CHF, the response to GH therapy appears to be variable.
METHODS Biochemical markers of the GH-insulin-like growth factor-I (IGF-I) axis were compared in
21 cachectic patients with CHF, 51 noncachectic patients and 26 healthy control subjects. In
separate studies, the predictive value of baseline biochemical variables for the IGF-I response
to GH treatment was analyzed.
RESULTS Cachectic patients showed an increase of total GH and immunologically intact GH (p #
0.0002) and a decrease of GH-binding protein (BP) (p 5 0.005), IGF-BP3 (p 5 0.01) and
IGF-I (p 5 0.06), compared with noncachectic patients. Similar changes were found when
the cachectic group was compared with the control group. No differences were found between
noncachectic patients and control subjects. Levels of GH-BP correlated with the IGF-I/GH
ratio in all subgroups (all p # 0.002). Baseline GH-BP levels were related to the increase of
IGF-I levels in response to GH treatment in patients with CHF after 24 h (r 5 0.83, p 5
0.005; n 5 9; study 2), 44 days (r 5 0.52, p 5 0.007; n 5 25; study 3) and 96 days (r 5 0.54,
p 5 0.006; n 5 24; study 3).
CONCLUSIONS Most cachectic and some noncachectic patients with CHF show features of acquired GH
resistance. The principal predictors of the biochemical features of GH resistance and of the
poor biochemical response to short-term and longer-term GH treatment are GH-BP plasma
levels. The presence of GH resistance is potentially a major factor determining the response
to GH therapy in patients with CHF. (J Am Coll Cardiol 2001;38:443–52) © 2001 by the
American College of Cardiology
Chronic heart failure (CHF) is a complex disease affecting
many body systems. Cachexia is known to occur in CHF,
and several metabolic pathways are involved in this syn-
drome, causing a catabolic/anabolic imbalance, including
the growth hormone (GH)-insulin-like growth factor-I
(IGF-I) system (1). Growth hormone is secreted from the
pituitary gland in a pulsatile manner and exerts direct
lipolytic effects, but its major mode of action is indirect and
anabolic through activation of the somatomedins (2). The
main GH-dependent somatomedin is IGF-I. Acquired GH
resistance is a feature of severe catabolism and malnutrition
in conditions of sepsis, surgery and critical illness (reviewed
in [3,4]). Biochemically, it is defined as the presence of high
GH but low IGF-I levels. The GH-IGF axis, in particular,
the presence of GH resistance, has not been studied in detail
in patients with CHF.
Pilot studies of the treatment of patients with CHF due
to dilated cardiomyopathy (5) or ischemic cardiomyopathy
(6) with recombinant human GH have shown favorable
effects, but another pilot study (7) reported no benefit.
Recently, randomized, controlled trials of GH treatment in
patients with CHF have not shown clinical benefit (8,9). In
these studies, the IGF-I response to GH was highly
variable, and the degree of IGF-I increase during GH
treatment was directly related to the increase of the left
ventricular mass (8).
A lack of GH receptors could cause GH resistance, and
its presence may prevent a beneficial response to GH
therapy. Growth hormone-binding protein (BP) is structur-
ally identical to the GH receptor ectodomain and is thought
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to reflect the cellular GH receptor status (10,11). It has not
been studied whether GH-BP plasma levels could predict
the IGF-I response to GH treatment.
We present the results of three parallel studies from three
heart failure centers. The first study analyzed the biochem-
ical characteristics of acquired GH resistance in prospec-
tively defined cachectic patients with CHF, compared with
noncachectic patients and healthy subjects (London, study
1). To validate the use of single blood samples to assess GH
and IGF-I, we investigated the relationship between fasting
and overnight blood samples in patients with CHF and
control subjects (Brescia, study 2). Finally, we investigated
the predictive value of baseline biochemical variables for the
IGF-I response to GH treatment in patients with CHF.
The periods of GH treatment were 24 h in study 2 (Brescia)
and three months in study 3 (Berlin).
METHODS
Study 1. PATIENTS AND CLINICAL CHARACTERISTICS. Be-
tween March 1992 and December 1996, 26 healthy control
subjects and 72 stable patients with CHF were investigated
(Table 1). The patients had a mean peak oxygen consump-
tion (treadmill exercise test [12]) of 16.5 6 0.7 ml/kg body
weight/min, compared with 36.1 6 1.4 ml/kg/min in
control subjects (p , 0.0001). The patients with CHF were
receiving stable drug treatment consisting of furosemide or
other diuretics (n 5 66), an angiotensin-converting enzyme
inhibitor (n 5 62), warfarin (n 5 27), digoxin (n 5 26),
aspirin (n 5 25), amiodarone (n 5 25) and nitrates (n 5
21). No patient had severe renal failure (all serum creatinine
levels ,255 mmol/l) or diabetes mellitus.
Twenty-one patients with CHF were defined as cachectic
(13), based on a history of $6 months of nonedematous,
weight loss .7.5% of their previous normal weight (weight
loss 12.5 6 1.5 kg [range 5.5 to 30]) over 2.8 6 0.6 years
(i.e., 6.4 6 1.0 kg/year and 16.2 6 1.7% of previous normal
weight; body mass index [BMI] 21.1 6 0.4 kg/m2). No
patient had clinical signs of an acute infection or other
primary cachectic states, such as cancer, severe liver or
thyroid disease. The remaining 51 noncachectic patients
(BMI 26.6 6 0.5 kg/m2, p , 0.0001 vs. cachectic patients)
had no history of significant weight loss in the two years
before this study. The maximal weight gain in this period
was 12 kg. When comparing cachectic with noncachectic
patients, peak oxygen consumption (15.1 6 1.4 vs. 17.1 6
0.9 ml/kg/min, p 5 0.23), left ventricular ejection fraction
(LVEF) (27 6 3% vs. 27 6 2%, p 5 0.93), treatment and
mean New York Heart Association (NYHA) functional
class (2.6 6 0.1 vs. 2.8 6 0.1, p 5 0.45) were not found to
be significantly different. This study group includes 16
control subjects and 53 patients in whom total GH and
IGF-I results were presented previously (1).
HUMORAL MEASUREMENTS. Venous blood samples (30 ml)
were collected in the morning, between 9 and 10 AM, after
a fasting period of $12 h and with the patient in the supine
position at rest for $20 min. After centrifugation, aliquots
were stored at 280°C until analysis. In all subjects, IGF-I
(Medgenix, Fleurus, Belgium; sensitivity 0.25 ng/ml by
radioimmunoassay [RIA]) and GH (Nichols Institute
Diagnostics, San Juan Capistrano, California; sensitivity
0.02 ng/ml by immunoradiometric assay [IRMA]) were
measured. The GH results measured by IRMA are pre-
sented in the figures and tables, except where otherwise
Abbreviations and Acronyms
BMI 5 body mass index
BP 5 binding protein
CHF 5 chronic heart failure
DEXA 5 dual-energy X-ray absorptiometric
GH 5 growth hormone
IGF-I 5 insulin-like growth factor-I
IRMA 5 immunoradiometric assay
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
RIA 5 radioimmunoassay
SC 5 standardized coefficient
Table 1. Clinical Details and Absolute Ratio of IGF-I to GH of Control Subjects (Study 1) and
Patients With CHF in Studies 1 to 3
Control
Subjects
(n 5 26)
Patients With CHF
Study 1
(n 5 72)
Study 2
(n 5 10)
Study 3
(n 5 24)
Age (yr) 56 6 2 61 6 1* 62 6 3 54 6 2
Weight (kg) 81 6 2 75 6 2 64 6 3 83 6 3
Height (cm) 176 6 1 173 6 1† 168 6 2 174 6 2
Body mass index (kg/m2) 26 6 1 25 6 0.5 24 6 1 27 6 1
Etiology: CAD/DCM (n) — 50/22 7/3 0/24
NYHA functional class — 2.7 6 0.1 3.0 6 0.2 2.3 6 0.6
LVEF (%) — 27 6 2 23 6 2 26 6 2
Log IGF-I/GH ratio 2.72 6 0.19 2.47 6 0.12 2.19 6 0.20 2.38 6 0.06
Absolute IGF-I/GH ratio 525 (1288; 2186) 295 (194; 271) 155 (191; 257) 240 (136; 231)
*p 5 0.07 vs. control subjects (in study 1). †p , 0.05 vs. control subjects (in study 1). Data are presented as the mean value 6
SEM, except for etiology and absolute IGF/GH ratio.
CAD 5 coronary artery disease; CHF 5 chronic heart failure; DCM 5 dilated cardiomyopathy; GH 5 growth hormone;
IGF-I 5 insulin-like growth factor-I; LVEF 5 left ventricular ejection fraction; NYHA 5 New York Heart Association.
444 Anker et al. JACC Vol. 38, No. 2, 2001
Growth Hormone Resistance in CHF August 2001:443–52
indicated. In 83 subjects (24 control subjects and 59
patients), measurement of the immunofunctionally intact
form of GH was performed by using an immunofunctional
assay, as previously published (14). This test has a lower
detection limit of 0.1 ng/ml. In 81 subjects (24 control
subjects and 57 patients), IGF-BP3 and GH-BP were
measured. For quantitative measurement of IGF-BP3, a
nonisotopic sandwich immunoassay was used (15). The
assay has a lower detection limit of 2.18 pg/tube. For
analysis of biologically intact GH-BP, a ligand immuno-
functional assay (16) that has a lower detection limit of 19.9
pM/l (0.5 fmol/well) was used: intra-assay coefficients of
variation were 3.4% at 115 pM/l and 5.9% at 1550 pM/l;
the inter-assay coefficients of variation were 8.5% and
10.9%, respectively.
BODY COMPOSITION. To assess whether potential alter-
ations of GH, IGF-I and, in particular, GH-BP, are a
reflection of fat tissue differences between cachectic and
noncachectic patients, we evaluated body composition using
dual-energy X-ray absorptiometric (DEXA) scanning (17).
In 58 patients (18 cachectic and 40 noncachectic), DEXA
scans were obtained (effective dose equivalent 0.002 mSv;
Lunar model DPX total body scanner, Lunar Radiation
Company, Madison, Wisconsin).
Study 2. OVERNIGHT PROFILES. In 10 patients with CHF
(2 cachectic) (Table 1) (18) and 9 healthy control subjects
(age 60 6 2 years, BMI 26 6 2 kg/m2, p 5 0.09), venous
blood samples were collected every 20 min between 10 PM
and 6 AM using an indwelling catheter in the brachial artery
(kept open through a saline infusion). Retrospectively, the
blood samples were used to study GH levels (at each time
point) and IGF-I levels (at three time points, every 4 h). To
validate the use of single blood samples for the assessment of
GH and IGF-I, the results of the overnight assessments
were compared with the hormone level results obtained in a
fasting blood sample taken between 7 and 8 AM after at least
20 min of supine rest after the end of the overnight
sampling procedure. After centrifugation, aliquots were
stored at 280°C until analysis. Growth hormone and IGF-I
were measured as described elsewhere (19). In 9 of the 10
patients with CHF, it was also possible to relate the increase
of IGF-I levels after a continuous intravenous infusion of
0.1 IU/kg GH over 24 h (Humatrope, Eli Lilly, Italy)
(18,19) with baseline GH-BP levels. Growth hormone-BP
was determined as described in study 1.
Study 3. RESPONSE OF IGF-I TO GH TREATMENT. The 25
patients with CHF in this study comprise the group of
actively treated patients described in detail previously (8).
None of these patients was cachectic. The clinical details of
these patients are compared with those of the patients in
studies 1 and 2 (Table 1). The patients in study 3 received
2 IU of GH daily (subcutaneous injections in the evening;
Genotropin, Pharmacia & Upjohn, Erlangen, Germany).
Venous fasting blood samples were collected in the morn-
ing, between 7 and 9 AM, after the patient rested in the
supine position for at least 20 min, on the day of random-
ization, after 44 6 1 days of treatment and at the end of the
treatment phase (mean 96 6 1 days). After centrifugation,
aliquots were stored at 280°C until analysis. Levels of
IGF-I, GH and GH-BP were determined as described
previously (8,20,21). The GH-BP RIA (tracer and stan-
dard; human recombinant GH-BP; batch 1070, kindly
provided by Pharmacia & Upjohn, Stockholm, Sweden) has
an intra-assay coefficient of variation of 9%.
MEASUREMENT OF GH-BP. It is important to note that the
two tests to measure GH-BP are based on different methods
(i.e., a ligand immunofunctional assay was used by Pflaum et
al. [16] and RIA was used as published by Blum and Breier
[20,21]). The first test kit is thought to measure functionally
intact GH-BP. The second test kit measures the absolute
quantity of GH-BP. The latter test kit could be influenced
by GH-BP fragments. It is difficult to directly compare the
results of the two analyses. Therefore, we present the
GH-BP data in their respective units, as originally reported.
To make these results comparable, we performed a test kit
validation for GH-BP with 65 subjects, including healthy
control subjects, patients with CHF and patients with a GH
deficiency (age 57 6 3 years). It was found that the results
of the two GH-BP assessments correlated very well (r 5
0.87, r2 5 0.75; GH-BP [pmol/l] 5 24,160 1 3,427 3
[GH-BP in ng/ml]). When transforming plasma levels of
functionally intact GH-BP into equivalent absolute levels of
GH-BP, we found that the coefficient of variance between
the two methods was 13.8%.
ANALYSES. All results are presented as the mean value 6
SEM. The chi-square test, Student t test, analysis of
variance and Fisher post hoc test were applied, as appropri-
ate. Simple, multivariate and stepwise regression analyses
were performed. A p value ,0.05 was considered signifi-
cant. Because of skewed distribution, log-transformed val-
ues were used for statistical analyses of the ratio of IGF-I to
GH (log IGF-I/GH) and for calculation of the proportion
of intact GH in percent total GH. All studies were
approved by the respective ethics committees, and patients
gave written, informed consent.
RESULTS
Study 1. REST MEASUREMENTS OF THE GH–IGF-I AXIS.
The results are shown in Table 2. When the patients with
CHF were subclassified according to the presence or ab-
sence of cachexia, major differences in the measures of the
GH-IGF axis were found. Noncachectic patients with CHF
and control subjects did not differ. The cachectic patients
with CHF, as a group, presented with the biochemical
characteristics of the syndrome of acquired GH resistance.
Compared with noncachectic patients with CHF, they had
increased GH levels (342%, p , 0.0001) and immunofunc-
tionally intact GH (229%, p 5 0.0002). The relative
proportion of immunologically functional (i.e., intact) GH
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(percent total GH [IRMA test]) was reduced in cachectic
patients with CHF (p 5 0.0005 vs. noncachectic patients; p 5
0.0012 vs. control subjects), although the total concentration of
intact GH remained highest in the cachectic subgroup (Table
2). The absolute IGF-I/GH ratio was 12-fold higher in
noncachectic than in cachectic patients with CHF (631
[1240; 2174] vs. 48 [121; 215], p , 0.0001). Compared
with noncachectic patients, the cachectic patients showed a
trend toward lower IGF-I (217%, p 5 0.06), reduced IGF-
BP3 (215%, p 5 0.01) and reduced GH-BP (236%, p 5
0.005). Consequently, the IGF-I/GH ratio was markedly
reduced in cachectic patients with CHF (Fig. 1A).
SUBGROUP ANALYSES. As there was considerable overlap of
the IGF-I/GH ratio in cachectic and noncachectic patients,
we have also analyzed the clinical characteristics of patients
in the lowest tertile of the IGF/GH ratios (n 5 24)
compared with the remaining 48 patients with CHF (Table
3). Patients with a low IGF/GH ratio were more frequently
cachectic and they had a lower peak oxygen consumption
(both p 5 0.006) and abnormal measures of the GH–IGF-I
axis (all p # 0.003), but LVEF, NYHA class and CHF
etiology were similar. In addition, we assessed the charac-
teristics of the 12 noncachectic patients with CHF with a
low IGF/GH ratio (from the group of patients in the overall
lowest tertile in the first comparison), and we compared
these patients with the 39 noncachectic patients with
normal to high IGF/GH ratios (log IGF-I/GH: 1.56 6
0.07 vs. 3.18 6 0.12). The noncachectic patients with a low
IGF/GH ratio had higher total GH levels (4.09 6 0.66 vs.
0.32 6 0.08 ng/ml, p , 0.0001), but otherwise the variables
of the GH–IGF-I axis were not altered (all p . 0.09).
Nevertheless, these noncachectic patients had a lower BMI
(24.6 6 0.5 vs. 27.3 6 0.6 kg/m2), and they showed signs
of sympathetic activation (noradrenaline: 3.78 6 0.63 vs.
2.43 6 0.21 nmol/l, p 5 0.026; adrenaline: 1.64 6 0.52 vs.
0.50 6 0.10 nmol/l, p 5 0.0011), although LVEF, NYHA
class and CHF etiology were similar (all p . 0.2).
CORRELATION ANALYSES. The clinical and biochemical
correlates of the log IGF-I/GH ratio are detailed in Table
4. The strongest predictor of the log IGF-I/GH ratio was
the GH-BP plasma concentration (Fig. 1B). In all patients
with CHF, on multivariate regression analysis with seven
variables—age, BMI, LVEF, NYHA class, adrenaline,
noradrenaline and GH-BP—only GH-BP (standardized
coefficient [SC] 0.45, p 5 0.0013) and noradrenaline (SC
20.40, p 5 0.011) were significantly related to the log
IGF-I/GH ratio (age: p 5 0.11; all other variables: p .
0.8). In a two-parameter model, GH-BP (SC 0.57) and
noradrenaline (SC 20.38, both p , 0.0001) were indepen-
dently related to the log IGF-I/GH ratio and jointly
predicted 61% of the variation of this variable.
On multivariate analysis for the predictors of GH-BP, in
all patients with CHF, percent ideal weight was predictive
(SC 0.56, p , 0.0001), but noradrenaline (p 5 0.13),
NYHA class, age and LVEF were not (all p . 0.3). In
cachectic patients, total weight loss (in percent of previous
weight) also correlated with GH-BP levels (r 5 20.60,
p50.004). In cachectic patients with CHF, IGF-BP3 was
closely related to GH-BP (r 5 0.70, p 5 0.0005; vs.
noncachectic patients: r 5 0.28, p 5 0.10; vs. control
subjects: r 5 0.16, p 5 0.44).
BODY COMPOSITION ANALYSES. Compared with nonca-
chectic patients (n 5 40), cachectic patients (n 5 18)
showed grossly reduced lean tissue content (268 6 6 vs.
327 6 5 g/cm height, p , 0.0001) and fat tissue content
(75 6 5 vs. 124 6 7 g/cm, p , 0.0001). Body composition
results in noncachectic patients were similar to those in
control subjects (data not shown). Fat and lean tissue
Table 2. Variables of the GH/IGF-I Axis in Healthy Control Subjects and Patients With CHF
Control Subjects
All Patients
With CHF
Noncachectic
Patients
With CHF*
Cachectic
Patients
With CHF†
Total GH (ng/ml) 1.22 6 0.31 2.40 6 0.47 1.20 6 0.28 5.31 6 1.29§/§
(n 5 26/72/51/21)
Intact GH (ng/ml) 0.53 6 0.12 1.05 6 0.20 0.58 6 0.14 1.91 6 0.47\/\
(n 5 24/59/38/21)
Percent intact/total GH 55.7 (15.9; 25.3) 47.1 (13.2; 23.0) 55.5 (14.5; 24.2) 35.0 (13.0; 22.8)¶/\
IGF-I (ng/ml)‡ 151 6 9 142 6 6 150 6 8 124 6 9#/#
(n 5 26/72/51/21)
IGF-BP3 (mg/ml) 3.75 6 0.14 3.49 6 0.12 3.70 6 0.13 3.13 6 0.21**/**
(n 5 24/57/36/21)
GH-BP (pmol/liter) 852 6 83 823 6 62 950 6 84 607 6 64#/¶
(n 5 24/57/36/21)
log IGF-I/GH ratio
(n 5 26/72/51/21)
2.72 6 0.19 2.47 6 0.12 2.80 6 0.14 1.68 6 0.16\/§
Data are from study 1 and are presented as the mean value 6 SEM. *Noncachectic patients with CHF had no history of weight
loss; †cachectic patients with CHF had a history of weight loss .7.5% compared with previous normal weight; ‡p 5 0.13 by
analysis of variance; #p , 0.10; **p , 0.05; ¶p , 0.01; \p , 0.001; §p , 0.0001 vs. control subjects and noncachectic patients
with CHF, respectively (logarithmic transformation of the ratio of intact to total growth hormone resulted in asymmetric
standard errors).
BP 5 binding protein; other abbreviations as in Table 1.
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content correlated with the log IGF-I/GH ratio in these 58
patients with CHF (both r 5 0.45, p 5 0.0004). In 46
patients, body composition could be related to GH-BP
levels (GH-BP vs. lean tissue content: r 5 0.44, p , 0.003;
GH-BP vs. fat tissue content: r 5 0.56, p , 0.0001). On
multivariate analysis of these 46 patients with CHF,
GH-BP was related to the log IGF-I/GH ratio (SC 0.52,
p 5 0.0001) independently of the fat tissue content (SC 0.31,
p 5 0.014; adjusted joint r2 5 0.49, p , 0.0001).
Study 2. OVERNIGHT PROFILES. In 10 patients with CHF
and 9 control subjects, early morning GH (2.00 6 0.73 vs.
1.07 6 0.16 ng/ml, p 5 0.25) and IGF-I levels (175 6 17
vs. 165 6 16 ng/ml, p 5 0.68), as well as the log IGF-I/GH
ratio (2.19 6 0.20 vs. 2.23 6 0.08, p 5 0.83), were found
to be not significantly different. In overnight blood samples
of these subjects, mean GH (12.45 6 2.65 vs. 2.91 6
1.20 ng/ml, p , 0.006), peak GH (24.42 6 4.97 vs. 8.43 6
1.42 ng/ml, p 5 0.009) and the ratio of mean to peak GH
(55.1 6 6.2% vs. 29.5 6 6.4%, p 5 0.01) were increased in
patients with CHF, whereas the nighttime mean log IGF-
I/GH ratio (1.09 6 0.16 vs. 1.94 6 0.10, p 5 0.0004) was
reduced in patients with CHF compared with control
subjects. Only in patients with CHF were close correlations
found between the morning log IGF-I/GH ratios and
overnight mean and peak GH levels (Fig. 2A and B) and
nighttime mean log IGF-I/GH ratio (r 5 0.78, p 5 0.007;
vs. control subjects: r 5 0.14, p 5 0.72).
RESPONSE OF IGF-I TO 24-H TREATMENT WITH GH. In nine
patients with CHF, intravenous infusion of 0.1 IU/kg GH
over 24 h increased plasma IGF-I levels by 97 6 18 ng/ml,
from 157 6 25 to 254 6 28 ng/ml. Baseline GH-BP levels
(mean 678 6 38 pmol/l [range 331 to 1,367]) strongly
predicted the IGF-I response (r2 5 0.693, p 5 0.005) (Fig.
2C).
Study 3. RESPONSE OF IGF-I TO THREE-MONTH TREAT-
MENT WITH GH. In 25 patients with CHF, the baseline
biochemical characteristics were GH 1.96 6 0.26 ng/ml,
IGF-I 140 6 11 ng/ml, log IGF-I/GH ratio 2.38 6 0.06
and absolute GH-BP 1.78 6 0.06 pg/ml (corresponds to a
mean level of functionally intact GH-BP of 1,940 6 206
pmol/l). After 44 days of GH treatment, the IGF-I plasma
levels were found to be increased by a mean of 123 6 15
pg/ml (p 5 0.0001 vs. baseline; n 5 25), and after 96 days,
the IGF-I increase, compared with baseline, amounted to
72 6 9 pg/ml (p 5 0.0001 vs. baseline, p 5 0.001 vs. 44
days; n 5 24). Baseline GH-BP levels correlated with the
IGF-I increases at 44 days (r 5 0.52, p 5 0.007) and at 96
days (r 5 0.54, p 5 0.006) (Fig. 3). The baseline log
IGF-I/GH ratio did not significantly correlate with the
change in IGF-I levels. No other baseline clinical marker
(age, NYHA class, LVEF or exercise time) correlated with
the change in IGF-I levels during GH treatment (8). On
multivariate analysis with these biochemical and clinical
variables, only baseline GH-BP (SC 20.52, p , 0.01)
predicted the change in IGF-I levels during GH treatment
(all other variables: p . 0.10).
SUBGROUP ANALYSES. From Figure 3, it appears that there
were two groups of responders to GH treatment—patients
with GH-BP levels ,1.6 ng/ml (n 5 8) and patients with
GH-BP levels .1.6 ng/ml (n 5 16). To describe these two
patient groups in more detail, Table 5 is provided. Patients
in the lowest tertile of GH-BP levels at baseline were
similar in terms of age, NYHA class and LVEF (all p .
0.20) to those patients with higher GH-BP levels, but they
had lower BMIs (p 5 0.024), higher noradrenaline levels
(p 5 0.02) and lesser increases of IGF-I levels during
treatment (p , 0.004). Although a low IGF-I response to
GH treatment is related to less increase in left ventricular
mass (8), GH-BP levels at baseline were not directly related
to the change in left ventricular mass.
Figure 1. (A) Relationship between circulating growth hormone (GH) and
insulin-like growth factor-I (IGF-I) levels (log IGF-I/GH ratio) in
patients with chronic heart failure (CHF) and healthy control subjects. (B)
Relationship between functionally intact GH-binding protein (BP) and the
log IGF-I/GH ratio. Data are from study 1 and are presented as the mean
value 6 SD. *p , 0.0001; **p 5 0.0001 vs. cachectic patients with CHF.
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DISCUSSION
This study shows that the presence of cachexia in patients
with CHF is linked to the biochemical pattern of acquired
GH resistance. This finding is supported by the demonstra-
tion that reduced fat and lean tissue content in patients with
CHF correlate with the abnormalities of the GH–IGF-I
axis. Also, in the absence of cachexia, a proportion of
patients with CHF appears to be hormonally resistant to
GH treatment. The principal predictor of the biochemical
features of GH resistance and poor biochemical response to
short-term and longer term GH treatment appears to be the
GH-BP plasma level. This strongly suggests that a reduc-
tion of tissue GH receptors is causal for the presence of GH
resistance.
The principal concept of GH resistance in patients with
CHF has been developed from data derived from a detailed
cross-sectional study (study 1), and methodologically, it is
supported by the analysis of GH overnight profiles (study
2). Growth hormone is secreted in a pulsatile fashion, and
this may make analyses using single morning blood samples
questionable. However, the results of study 2 suggest that in
patients with CHF, single morning blood samples assessing
the IGF-I/GH ratio may be useful to characterize the
GH–IGF-I axis in patients with CHF. To prove the
concept of GH resistance determining the response to GH
treatment, we have presented data on 25 patients treated
with GH in a controlled trial for three months (study 3 [8]).
To date, this is the largest group of patients with CHF
Table 3. Clinical and Biochemical Characteristics of Patients With CHF in the Lowest Tertile
of the Log Ratio of IGF-I to GH, Compared With Patients in the Two Upper Tertiles in
Study 1
Patients With CHF
in the Lowest
Tertile of
Log IGF-I/GH
(n 5 24)
Patients With CHF
in the Second and
Third Tertile of
Log IGF-I/GH
(n 5 48)
p
Value
Age (yr) 66 6 2 59 6 2 0.010
Weight (kg) 69 6 2 78.8 6 2 0.0005
Height (cm) 172 6 1 173 6 1 0.36
Body mass index (kg/m2) 22.6 6 0.5 26.2 6 0.6 0.0003
Etiology
CAD 14 (58%) 30 (62%) 0.73
DCM 10 (42%) 18 (38%)
Presence of cachexia
Yes 12 (50%) 9 (19%) 0.006
No 12 (50%) 39 (81%)
NYHA functional class 2.8 6 0.2 2.6 6 0.1 0.48
LVEF 25 6 3 28 6 2 0.36
Peak oxygen consumption (ml/kg/min) 13.6 6 1.2 17.9 6 0.9 0.006
Total GH (ng/ml) 6.4 6 1.0 0.4 6 0.07 ,0.0001
Intact GH (ng/ml) 2.47 6 0.39 0.21 6 0.03 ,0.0001
IGF-I (ng/ml) 116 6 8 156 6 8 0.003
Log (IGF-I/GH) 1.34 6 0.07 3.04 6 0.11 —
IGF-BP3 (mg/ml) 2.87 6 0.15 3.83 6 0.13 ,0.0001
GH-BP (pmol/l) 581 6 86 954 6 75 0.003
Data are presented as the mean value 6 SEM or number (%) of patients.
BP 5 binding protein; CAD 5 coronary artery disease; CHF 5 chronic heart failure; DCM 5 dilated cardiomyopathy;
GH 5 growth hormone; IGF-I 5 insulin-like growth factor-I; LVEF 5 left ventricular ejection fraction; NYHA 5 New York
Heart Association.
Table 4. The Relationship of the Biochemical Marker of GH Resistance (IGF-I/GH log ratio)
to Clinical and Biochemical Variables in Healthy Control Subjects and Patients With CHF*
Variable
All
Subjects
Control
Subjects
All Patients
With CHF
Noncachectic
Patients
With CHF
Cachectic
Patients
With CHF
Age 20.41* 20.26 20.45* 20.35† 20.26
Body mass index 0.48* 0.23 0.54* 0.37‡ 0.22
Percent ideal weight 0.48* 0.23 0.54* 0.37‡ 0.20
LVEF — — 0.04 20.06 0.36
NYHA functional class — — 20.20 20.11 20.49†
Peak oxygen consumption 0.21† 20.07 0.35‡ 0.28† 0.48†
IGF-BP3 0.36‡ 0.06 0.43§ 0.24 0.52†
GH-BP 0.65* 0.79* 0.61* 0.50‡ 0.68§
*Data are from study 1. Regression coefficients of simple linear regression: *p , 0.0001, †p , 0.05, ‡p , 0.01, §p , 0.001.
Abbreviations as in Table 3.
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available for such analyses. The main finding of study 3 (i.e.,
the direct relationship between baseline GH-BP levels and
the IGF-I response to GH treatment, p 5 0.006) was
confirmed with data from study 2 (18). In this study, as well,
baseline GH-BP levels strongly correlated with the changes
in IGF-I levels after GH treatment (duration 24 h, p 5
0.005).
Like resistance to the action of insulin (22), GH resis-
tance may be a potentially important hormonal resistance
syndrome in CHF. In particular, in noncachectic patients
with a low IGF/GH ratio (study 1), it was interesting to
note that these patients showed signs of sympathetic acti-
vation and lowered BMI, although they had not (yet)
developed weight loss as a consequence. Also, the patients
with low GH-BP levels and an impaired IGF-I response in
study 3 had a lower BMI and higher noradrenaline levels.
These noncachectic patients may be metabolically similar to
cachectic patients. Potentially, the noncachectic patients
with a low IGF/GH ratio are those who are at a higher risk
of developing cachexia and may be (already) GH resistant.
Cardiac cachexia is independently related to impaired sur-
vival in patients with CHF (23). Interestingly, in patients
with liver cirrhosis also, low IGF-I responses to GH were
related to impaired survival (24).
On multivariate analyses, the main predictor of a lower
IGF-I/GH ratio (as the main indicator of GH resistance)
was a lower level of GH-BP. As GH-BP levels reflect the
cellular GH receptor status (10,11), the development of GH
resistance may be due to changes at the cellular level. These
changes occur independently of age, peak VO2, LVEF and
NYHA class, and GH resistance cannot be predicted from
these conventional markers of disease severity. It could be
argued that the reduced fat tissue content, by itself, in
cachectic patients may contribute to a reduction of GH-BP
(25), leading to a reduced IGF-I/GH ratio. However, in
study 1, the relationship between GH-BP levels and the
IGF-I/GH ratio was much stronger and independent of the
fat tissue content in these patients. The decreased ratio of
immunofunctionally intact GH to total GH in the cachectic
subgroup (35% vs. 56% in noncachectic patients and control
subjects) can be interpreted as further indirect evidence of a
decreased GH–GH-receptor interaction in these patients,
consequently leading to an increased proteolytic degradation
of GH in the circulation.
Growth hormone treatment in patients with CHF. In
several reviews and commentaries, the importance of GH as
an active cardiovascular drug and its possible impact on
treatment of patients with CHF have recently been dis-
cussed (26,27), although no clear picture emerges. In 1996,
a pilot study of seven patients with CHF showed that
cardiac function and exercise tolerance improved after three
months of treatment with GH (14 IU/week) (5). Frustaci et
al. (7) were not able to document any significant benefit of
three months of treatment with GH (n 5 5, dose 28
IU/week). Recent randomized, controlled studies investi-
gating the effects of GH in a total group of 72 patients with
CHF (2 IU/day) (8,9) have shown that GH treatment is
safe, but it did not improve NYHA class, LVEF, 6-min
walking time or neurohormonal status. In the larger study
(n 5 50, [8]) the only significant nonhormonal effect of GH
treatment was an increase of left ventricular mass, as
assessed by magnetic resonance imaging. Isgaard et al. (9)
were not able to confirm this using echocardiography.
Previously, hemodynamic benefit of 24-h intravenous GH
infusion has been reported (18), but in randomized studies
(8), this could not be confirmed. Recently, Genth-Zotz et
al. (6) reported that GH treatment for three months (2
IU/day) over a period of three months significantly im-
proved hemodynamic data, clinical status and exercise ca-
pacity in patients with ischemic cardiomyopathy. A recent
study confirmed these results in patients with moderately
severe CHF secondary to coronary artery disease (dose 0.02
IU/kg/day, duration 6 months [28]). If the differences
between the studies are not entirely due to the placebo effect
of GH treatment, the reasons for the differing results must
rest with the patient groups studied, as the treatment
Figure 2. Relationship between the log insulin-like growth factor-I/
growth hormone (IGF-I/GH) ratio (from a single sample in the morning)
and mean (A) and peak (B) GH levels in 8-h overnight blood samples
(study 2). **p , 0.01 vs. control subjects. (C) Relationship between
baseline GH-binding protein (BP) levels and the IGF-I response to GH (2
IU/day for 24 h) in nine patients with chronic heart failure (CHF) (study
2) (polynomial correlation: r 5 0.90, p 5 0.006).
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scheme was similar in all studies. Conventional markers of
disease severity were also similar in the different trials.
Therefore, the observed differences may be due to metabolic
differences that may exist, but were not assessed, between
patients.
Therapeutic implications. We have demonstrated that, in
particular, cachectic patients, but also some noncachectic
patients with CHF show the characteristics of acquired GH
resistance, and this may prevent a beneficial response to GH
therapy. From our studies, it may be estimated that ;60%
to 70% of cachectic patients with CHF and 20% to 30% of
noncachectic patients with CHF are GH resistant. In the
future, it may be considered beneficial to recruit patients for
GH treatment on the basis of baseline GH-BP plasma
levels, or on the basis of the first-dose IGF-I response to a
test dose of GH (29). Future studies would need to
prospectively determine useful cut-off values. Theoretically,
there are several possibilities to overcome GH resistance in
patients with CHF. First, the therapeutic dose of GH could
be increased, although this is generally thought to be risky
because of the many possible side effects (e.g., promotion of
a diabetogenic condition, sympathetic activation or sodium/
water retention and carpal tunnel syndrome) (30). Recently,
the results of GH treatment using 5.3 mg (16 IU) or 8.0 (24
IU) mg/day, compared with placebo, in critically ill adults
who had been in an intensive care unit for five to seven days
due to cardiac surgery, abdominal surgery, multiple trauma
or acute respiratory failure were reported (31). In these
studies, mortality in the GH treatment group was about
twofold higher than that in the placebo group. The majority
of the deaths was attributable to multiple organ failure and
septic shock or uncontrolled infection, and .50% of the
deaths occurred in the first 10 days of treatment. It has been
suggested that the outcome of these patients after GH
treatment was poor, because these patients very likely did
not have systemic inflammation and neurohormonal activa-
tion as a component of their disease (32). Among patients
with CHF, those with cachexia clearly show the highest
plasma levels of catecholamines and inflammatory cytokines
(1,17).
The intensive care trials (31) did not aim to achieve
Figure 3. Relationship between growth hormone-binding protein (GH-
BP) levels at baseline and biochemical (insulin-like growth factor-I
[IGF-I]) response to GH (2 IU/day for 14 weeks) in 24 patients with
chronic heart failure. Data are from study 3.
Table 5. Clinical and Biochemical Characteristics of Patients With CHF in the Lowest Tertile*
of GH-Binding Protein Levels at Baseline, Compared With Patients in the Two Other Tertiles
in Study 3
Patients in Lowest
Tertile of GH-BP
Levels at Baseline
(n 5 8)
Patients in Second or Third
Tertile of GH-BP
Levels at Baseline
(n 5 16) p Value
Age (years) 57 6 4 53 6 3 0.34
Weight (kg) 75.6 6 5.6 86.6 6 3.8 0.11
Height (cm) 175 6 3 173 6 2 0.61
Body mass index (kg/m2) 24.5 6 1.4 28.8 6 1.1 0.024
NYHA functional class 2.6 6 0.2 2.2 6 0.2 0.23
LVEF 25 6 5 27 6 2 0.68
Noradrenaline (pg/ml) 489 6 133 229 6 30 0.02
Total GH (ng/ml) 1.59 6 0.21 1.70 6 0.16 0.69
IGF-I (ng/ml) 105 6 21 148 6 10 0.049
IGF-I (ng/ml), change from
baseline
141 6 9 1100 6 12 0.0036
Log (IGF-I/GH) 1.78 6 0.15 1.95 6 0.04 0.20
GH-BP (ng/ml) 1.42 6 0.05 1.97 6 0.05 —
Left ventricular mass 262 6 7 228 6 18 0.24
Increase in left ventricular mass,
change from baseline
122 6 12 132 6 8 0.47
*Cut-off value for lowest tertile was 1.6 ng/ml (absolute GH-BP), corresponding to a level of 1324 pmol/l for functionally intact
GH-BP (see Methods). Data are presented as the mean value 6 SEM.
Abbreviations as in Table 3.
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anabolic effects on lean tissue; however, this would be the
aim of treating cachectic patients with CHF. The metabolic
status of cachectic patients with CHF is somewhat compa-
rable to that of patients with AIDS-associated wasting, and
these patients also show the biochemical characteristics of
GH resistance. In the U.S., higher dose GH therapy has
been approved by the Food and Drug Administration for
use in treating AIDS-associated wasting (subcutaneous
injections of 4 to 6 mg/day [12 to 18 IU/day]) (33). Most
common side effects include increases of tissue turgor
complex and musculoskeletal discomfort (34). The experi-
ence with anabolic doses of GH in patients with CHF is
very limited. Two case reports (35,36) with three cachectic
patients with CHF demonstrated that short periods (1 week
to 3 months) of high-dose GH therapy (70 to 98 IU/week)
resulted in profound increases of muscle mass, strength and
exercise capacity, with no reported side effects. Alterna-
tively, IGF-I itself might be given; IGF-I can reverse
weight loss induced by starvation (37) and can induce
hypoglycemia (the immediate effectiveness of IGF com-
pared with insulin in healthy adults is ;6% [38]) and also
peripheral edema (30). This treatment approach might be
considered problematic, because high IGF-I levels correlate
with an increased risk of breast cancer development in
premenopausal women ,50 years old (but not in postmeno-
pausal women) (39) and with the risk of prostate cancer in
men (40). Nevertheless, these studies have not assessed the
relationship between IGF-I and survival, which is impor-
tant, because high IGF-I levels are also linked to better
nutritional status (41) and improved survival in patients
with severe liver disease (42). Interestingly, a study in dogs
with heart failure has shown that high IGF-I levels relate to
better survival (43). The combination of GH and IGF-I will
have a powerful anabolic action, may overcome GH resis-
tance and may minimize side effects (3,44). On the basis of
the results of the present study, we aim to perform treat-
ment studies in patients with cardiac cachexia similar to
those done in cachectic patients with AIDS. However, the
GH doses we plan to use would be ;50% below the doses
used in the intensive care unit trials (31).
Study limitations. This report is a cooperative statement
of the participating investigators on the relevance and
significance of GH therapy and GH resistance in patients
with CHF. We are aware that there are limitations to our
approach of combining data from three distinct studies, but
we believe this also has distinct advantages. Our studies
provide circumstantial evidence. Nevertheless, we believe
that the concept of GH resistance is logical, and definitive
proof could only be obtained if future studies take this issue
into account. Until then, we may continue to see a number
of studies grossly differing in outcome. The issue of inter-
changeability of data from the study groups is particularly
important. We have tried to establish that CHF and disease
etiology were defined similarly in each study. The issues of
definition and assessment of CHF were discussed, but only
marginal differences were found, mainly due to availability
of resources. Blood samples were always taken in the fasting
state. Some differences in analytic procedures remain. The
two methods for assessing GH-BP are different; however,
the results correlate well, and with both test kits, a correla-
tion between GH-BP and the subsequent increase of IGF-I
levels was found (in studies 2 and 3). In addition, the overall
sample size is relatively small (particularly for study 3,
although it is the world’s largest available). Our results did
not depend on an arbitrary definition of cachexia. Using
other definitions of significant weight loss (e.g., ideal weight
,90% or ,85%), similar differences in the GH–IGF-I axis
were found (data not shown).
Conclusions. Cachectic patients with CHF show features
of acquired GH resistance. This resistance may be mediated
by a reduction of GH receptors and may contribute causally
to the syndrome of cardiac cachexia. Also, some noncachec-
tic patients show GH resistance. The presence or develop-
ment of GH resistance may influence the response to GH
therapy. Assessment of the GH–IGF-I axis before GH
administration may increase the effectiveness of this treat-
ment approach.
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